A review of the potential of poly-(lactide-co-glycolide) nanoparticles as a delivery system for an active antimycobacterial compound, 7-methyljuglone
JavaScript is disabled for your browser. Some features of this site may not work without it.
Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.
| dc.contributor.author | Diedericks, B.
|
|
| dc.contributor.author | Kok, Anna-Mari
|
|
| dc.contributor.author | Mandiwana, Vusani
|
|
| dc.contributor.author | Lall, Namrita
|
|
| dc.date.accessioned | 2025-04-08T12:57:47Z | |
| dc.date.available | 2025-04-08T12:57:47Z | |
| dc.date.issued | 2024-02 | |
| dc.description | DATA AVAILABILITY STATEMENT: Data are contained within the article. | en_US |
| dc.description | This article belongs to the special issue titled 'Current Applications in Plant-Based Drug Delivery Nano Systems'. | en_US |
| dc.description.abstract | 7-Methyljuglone (7-MJ) is a pure compound isolated from the roots of Euclea natalensis A. DC., a shrub indigenous to South Africa. It exhibits significant promise as a potential treatment for the highly communicable disease tuberculosis (TB), owing to its effective antimycobacterial activity against Mycobacterium tuberculosis. Despite its potential therapeutic benefits, 7-MJ has demonstrated in vitro cytotoxicity against various cancerous and non-cancerous cell lines, raising concerns about its safety for consumption by TB patients. Therefore, this review focuses on exploring the potential of poly-(lactide-co-glycolic) acid (PLGA) nanoparticles as a delivery system, which has been shown to decrease in vitro cytotoxicity, and 7-MJ as an effective antimycobacterial compound. | en_US |
| dc.description.department | Plant Production and Soil Science | en_US |
| dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
| dc.description.sdg | SDG-09: Industry, innovation and infrastructure | en_US |
| dc.description.sponsorship | The National Research Foundation (NRF). | en_US |
| dc.description.uri | https://www.mdpi.com/journal/pharmaceuticals | en_US |
| dc.identifier.citation | Diedericks, B.; Kok, A.-M.; Mandiwana, V.; Lall, N. A Review of the Potential of Poly-(lactide -co-glycolide) Nanoparticles as a Delivery System for an Active Antimycobacterial Compound, 7-Methyljuglone. Pharmaceutics 2024, 16, 216. https://doi.org/10.3390/pharmaceutics16020216. | en_US |
| dc.identifier.issn | 1424-8247 (online) | |
| dc.identifier.other | 10.3390/pharmaceutics16020216 | |
| dc.identifier.uri | http://hdl.handle.net/2263/101921 | |
| dc.language.iso | en | en_US |
| dc.publisher | MDPI | en_US |
| dc.rights | © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). | en_US |
| dc.subject | Tuberculosis (TB) | en_US |
| dc.subject | Antimycobacterial | en_US |
| dc.subject | Cytotoxicity | en_US |
| dc.subject | 7-methyljuglone | en_US |
| dc.subject | Poly-(lactide-co-glycolide) (PLGA) | en_US |
| dc.subject | Nanoparticle | en_US |
| dc.subject | SDG-03: Good health and well-being | en_US |
| dc.subject | SDG-09: Industry, innovation and infrastructure | en_US |
| dc.title | A review of the potential of poly-(lactide-co-glycolide) nanoparticles as a delivery system for an active antimycobacterial compound, 7-methyljuglone | en_US |
| dc.type | Article | en_US |
